Dynamic regulation of IL-33 in the obesity pathogenesis: Spatiotemporal specificity and functional paradoxes
Authors:
- 2 September 2025
- journal article
- review article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 229, 112455
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Hunan Province (2025JJ50611)
- National Key Research and Development Program of China (2022YFC2505200)
This publication has 101 references indexed in Scilit:
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled StudyThe Journal of Clinical Pharmacology, 2023
- Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseasesCytokine & Growth Factor Reviews, 2023
- Interleukin-33 inhibits glucose uptake in human adipocytes and its expression in adipose tissue is elevated in insulin resistance and type 2 diabetesCytokine, 2022
- Why does obesity cause diabetes?Cell Metabolism, 2022
- IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in miceBiotechnology Letters, 2020
- Heterogeneity in Obesity: Genetic Basis and Metabolic ConsequencesCurrent Diabetes Reports, 2020
- Associations of IL1RAP and IL1RL1 gene polymorphisms with obesity and inflammation mediatorsInflammation Research, 2020
- IL-33 in obesity: where do we go from here?Inflammation Research, 2019
- PD-1 Is Involved in the Dysregulation of Type 2 Innate Lymphoid Cells in a Murine Model of ObesityCell Reports, 2018
- Novel pharmacological approaches to combat obesity and insulin resistance: targeting skeletal muscle with ‘exercise mimetics’Diabetologia, 2009